Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

personal health monitoring

- PMLiVE

Novartis shares positive real-world data for Leqvio in atherosclerotic CVD

LDL-C is a causal risk factor for ASCVD and increases the risk of heart disease and stroke

- PMLiVE

BMS and Shine Cancer Support’s UK research reveals disparities in cancer diagnosis

The Cancer Equals campaign and 1,000 Voices, Not 1 report aim to help address reasons for diagnostic delays

- PMLiVE

Scientists recommend new imaging technique to support design of innovative cancer drugs

Cryo-EM helped to determine the detailed structures of CAK, a promising target for cancer drugs

- PMLiVE

Autoimmune conditions: Living With syndicated patient reports

The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our...

Research Partnership

- PMLiVE

Mile High Impact at AAN 2024

The Medscape team will be joining our neurology colleagues in Denver, CO for this year’s AAN Annual Meeting. Impact will take center stage at this year’s event as Medscape presents...

Medscape Education Global

- PMLiVE

Everything Was Peachy at ACC 2024 in Atlanta, GA

The annual ACC meeting has officially wrapped up in Atlanta, bringing a successful conference to a close for another year.  During the conference, members of the Medscape team hosted a...

Medscape Education Global

- PMLiVE

MHRA approves TMC Pharma’s Nulibry to treat rare genetic disease MoCD type A

Molybdenum cofactor deficiency is estimated to affect one in 100,000 to 200,000 newborns worldwide

- PMLiVE

Merck acquires Abceutics in deal worth $208m to improve safety of ADCs

As part of the deal, Merck will gain access to the start-up’s payload selectivity enhancer technology

- PMLiVE

Pfizer shares positive late-stage results for RSV vaccine Abrysvo in high-risk adults

There are currently no vaccines approved for use in adults aged 18 to 59 years

- PMLiVE

New study reveals discrepancies in FDA accelerated approval process for cancer drugs

The study looked at 46 different cancer drugs that received accelerated approvals between 2013 and 2017

- PMLiVE

The killer question

Expert strategists ask four crucial questions – the first one confounds most of us

- PMLiVE

BMS and 2seventy’s multiple myeloma therapy Abecma receives expanded FDA approval

More than 35,700 new cases of the disease are expected to be diagnosed in the US this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links